The Risk of Pneumothorax With Intrapleural Urokinase in Children With Parapneumonic Effusion.

Autor: Kadmon G; Pediatric Intensive Care Unit, Schneider Children's Medical Center in Israel, Petach Tikva, Israel.; Faculty of Medicine and Health Science, Tel Aviv University, Tel Aviv, Israel., Schoen A; Pediatrics B Ward, Schneider Children's Medical Center in Israel, Petach Tikva, Israel., Nahum E; Pediatric Intensive Care Unit, Schneider Children's Medical Center in Israel, Petach Tikva, Israel., Weissbach A; Pediatric Intensive Care Unit, Schneider Children's Medical Center in Israel, Petach Tikva, Israel., Kaplan E; Pediatric Intensive Care Unit, Schneider Children's Medical Center in Israel, Petach Tikva, Israel., Cohen T; Pediatrics B Ward, Schneider Children's Medical Center in Israel, Petach Tikva, Israel., Chodick G; Faculty of Medicine and Health Science, Tel Aviv University, Tel Aviv, Israel.; School of Public Health, Tel Aviv University, Tel Aviv, Israel., Scheuerman O; Faculty of Medicine and Health Science, Tel Aviv University, Tel Aviv, Israel.; Pediatrics B Ward, Schneider Children's Medical Center in Israel, Petach Tikva, Israel.
Jazyk: angličtina
Zdroj: Pediatric pulmonology [Pediatr Pulmonol] 2024 Dec 13, pp. e27443. Date of Electronic Publication: 2024 Dec 13.
DOI: 10.1002/ppul.27443
Abstrakt: Aim: Fibrinolytic therapy is commonly used in children with parapneumonic effusion, to facilitate drainage of the effusions and recovery. However, data regarding complications of this treatment in children are limited. We aimed to determine the incidence of pneumothorax (PNX) associated with intrapleural urokinase.
Methods: We analyzed retrospectively collected data of children with parapneumonic effusion who underwent chest drain insertion. The clinical course and complications, including the incidence of PNX, were compared between children who were and were not treated with urokinase.
Results: The study group included 120 children, of whom 57 were treated with urokinase. Children who were and were not treated with urokinase did not differ in markers of disease severity or in the length of hospitalization. Among the patients treated with urokinase compared to those not treated, the incidence of PNX was higher (35% vs. 6%, p < 0.001) and the median duration of chest drain treatment was longer (6 vs. 4 days, p < 0.001).
Conclusion: In our pediatric cohort, intrapleural urokinase was associated with a higher incidence of PNX and did not shorten the duration of hospitalization.
(© 2024 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: